The Good Participatory Practice Guidelines have been shaping and improving HIV prevention research since 2007. They provide a global reference guide for ethical and effective stakeholder engagement, helping ensure the priorities of trial participants and their communities are centered in clinical trials and broader research agendas.
Over the past 16 years, the original GPP guidelines for HIV prevention have been issued in 10 languages and adapted to other disease areas, including tuberculosis, COVID-19, and emerging pathogens. GPP has given rise to a robust global community of practice, with an expansive history of lessons learned and success stories for the world to build upon.
GPP for Biomedical HIV Prevention Trials
The Good Participatory Practice (GPP) Guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV Prevention Trials.
- Engaging Stakeholders in Biomedical Research During the Era of COVID 19 — Published by AVAC
- GPP for Tuberculosis Vaccine Research — Published by Aeras
- GPP for Tuberculosis Drug Research — Published by Critical Path to TB Drug Regimens
- GPP for Trials for Emerging Pathogens — Published by WHO
- Stakeholder Input for GPP in Biomedical HIV Prevention Trials in Thailand — Published by the Thai Treatment Action Group
- GPP referenced as a key resource for ensuring ethical research — US President Barack Obama’s Commission for the Study of Bioethical Issues
Translations: GPP for Biomedical HIV Trials
Arabic: تحميل النسخة العربية هنا.
English: Download here.
Portuguese: Baixar versão em Português aqui.
Russian: Скачать русскую версию здесь.
Vietnamese: Tải phiên bản tiếng Việt ở đây.